T. Rowe Price Associates’s Pulmonx LUNG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98K | Buy |
37,730
+1,588
| +4% | +$4.13K | ﹤0.01% | 2895 |
|
|
2025
Q1 | $244K | Buy |
36,142
+2,557
| +8% | +$17.3K | ﹤0.01% | 2549 |
|
|
2024
Q4 | $229K | Sell |
33,585
-9,423
| -22% | -$64.3K | ﹤0.01% | 2617 |
|
|
2024
Q3 | $357K | Buy |
43,008
+299
| +0.7% | +$2.48K | ﹤0.01% | 2400 |
|
|
2024
Q2 | $271K | Buy |
42,709
+6,989
| +20% | +$44.3K | ﹤0.01% | 2462 |
|
|
2024
Q1 | $332K | Buy |
35,720
+1,633
| +5% | +$15.2K | ﹤0.01% | 2389 |
|
|
2023
Q4 | $435K | Buy |
34,087
+580
| +2% | +$7.4K | ﹤0.01% | 2234 |
|
|
2023
Q3 | $347K | Buy |
33,507
+3,749
| +13% | +$38.8K | ﹤0.01% | 2276 |
|
|
2023
Q2 | $391K | Buy |
29,758
+2,963
| +11% | +$38.9K | ﹤0.01% | 2243 |
|
|
2023
Q1 | $300K | Buy |
26,795
+691
| +3% | +$7.74K | ﹤0.01% | 2342 |
|
|
2022
Q4 | $220K | Buy |
26,104
+708
| +3% | +$5.97K | ﹤0.01% | 2491 |
|
|
2022
Q3 | $424K | Buy |
25,396
+2,033
| +9% | +$33.9K | ﹤0.01% | 2207 |
|
|
2022
Q2 | $344K | Buy |
23,363
+2,377
| +11% | +$35K | ﹤0.01% | 2381 |
|
|
2022
Q1 | $521K | Sell |
20,986
-197
| -0.9% | -$4.89K | ﹤0.01% | 2314 |
|
|
2021
Q4 | $679K | Sell |
21,183
-390,204
| -95% | -$12.5M | ﹤0.01% | 2233 |
|
|
2021
Q3 | $14.8M | Buy |
411,387
+21,860
| +6% | +$787K | ﹤0.01% | 1366 |
|
|
2021
Q2 | $17.2M | Sell |
389,527
-328,396
| -46% | -$14.5M | ﹤0.01% | 1335 |
|
|
2021
Q1 | $32.8M | Buy |
717,923
+348,008
| +94% | +$15.9M | ﹤0.01% | 1147 |
|
|
2020
Q4 | $25.5M | Buy |
+369,915
| New | +$25.5M | ﹤0.01% | 1157 |
|